| 8/4/2020 | Complete List of Licensed Products and Establishments |
| 8/4/2020 | Complete List of Substantially Equivalent 510(k) Device Applications |
| 8/4/2020 | Complete List of Currently Approved Premarket Approvals (PMAs) |
| 8/4/2020 | Complete List of Currently Approved NDA and ANDA Application Submissions |
| 8/3/2020 | BK200491 - iWeBB electronic Laboratory Information System (iWeBB-eLIS) v1.0.0 |
| 8/3/2020 | Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations |
| 8/3/2020 | MedWatch to Manufacturer Program |
| 7/31/2020 | CBER-Regulated Products: Resolved Shortages |
| 7/31/2020 | CBER-Regulated Products: Current Shortages |
| 7/29/2020 | Influenza Vaccine for the 2020-2021 Season |
| 7/28/2020 | Influenza neuraminidase antigenicity and efficacy in vaccines |
| 7/28/2020 | July 28, 2020 Approval Letter - MENVEO |
| 7/28/2020 | |
| 7/28/2020 | User Fee Billable Biologic Products and Potencies Approved Under Section 351 of PHS Act |
| 7/28/2020 | July 22, 2020 Untitled Letter - American Medical Aesthetics and Regenerative Medicine Inc. |
| 7/24/2020 | July 24, 2020 Approval Letter - TECARTUS |
| 7/24/2020 | CBER-Regulated Products: Current Shortages |
| 7/22/2020 | 2020 Biological Device Application Approvals |
| 7/22/2020 | 2020 Biological License Application Approvals |
| 7/22/2020 | 2020 Biological License Application Supplement Noteworthy Approvals |
| 7/22/2020 | Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes |
| 7/22/2020 | Reporting Adverse Events Related to Stem Cells, Exosomes, or Other Products Marketed as Regenerative Medicine Products |
| 7/20/2020 | TRG Rapid Inquiry Program (TRIP) |
| 7/20/2020 | Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use; Guidance for Industry and Food and Drug Administration Staff |
| 7/16/2020 | Considerations for the Use of Real-World Evidence to Assess the Effectiveness of Preventive Vaccines |
| 7/14/2020 | Diagnosis and Pathogenesis of Hepatitis Viruses That Impact the Safety of Blood and Related Products |
| 7/13/2020 | Understanding the Interplay Between Host Immunity and Viral Factors for Rational Design of Vaccines Against Vector-Borne Viral Pathogens |
| 7/10/2020 | Study of antibody response to SARS-CoV-2 spike proteins could help inform vaccine design |
| 7/10/2020 | July 9, 2020 Approval Letter - FluMist |
| 7/9/2020 | Regenerative Medicine Advanced Therapy Designation |
| 7/7/2020 | Summary of Safety and Effectiveness - Alinity m HIV-1 |
| 7/6/2020 | July 2, 2020 Approval Order - Alinity m HIV-1 |
| 7/6/2020 | July 2, 2020 Approval Letter - Flucelvax |
| 7/6/2020 | July 2, 2020 Approval Letter - Fluad and Fluad Quadrivalent |
| 7/6/2020 | July 2, 2020 Approval Letter - FluLaval |
.png)
No hay comentarios:
Publicar un comentario